Clinical Trial Update: Clinical Trial to Evaluate the Safety and Immunogenicity of Ferritin Nanoparticles Expressing Native-like HIV-1 Envelope Trimers Followed by Boost With mRNA Lipid Nanoparticles Encoding a Native-like HIV-1 Envelope Trimer in Adults Without HIV [Phase 1]

View source ↗

Summary

Phase 1 trial to assess the safety and immunogenicity of ferritin nanoparticle HIV envelope trimers followed by an mRNA lipid nanoparticle boost in adults witho…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• HIV Infection

Drugs mentioned

• Ferritin nanoparticle vaccine expressing native-like HIV-1 envelope trimers (ferritin nanoparticle HIV envelope trimer vaccine)
• mRNA lipid nanoparticle encoding native-like HIV-1 envelope trimer boost (mRNA-LNP HIV envelope trimer booster)

Snippet

Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) | Conditions: Hiv | Phase 1 | Status: ACTIVE_NOT_RECRUITING